

Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations

Eliminating microscopic residual disease with α -particle radiation is theoretically appealing. Following extensive preclinical work with α -particle emitting astatine-211 (211At), we performed a phase I trial in epithelial ovarian cancer (EOC). This was a first-in-class intraperitoneal (i.p.) α -particle therapy and the first in human study using the conjugate 211At-MX35, a murine monoclonal F(ab')₂ antibody. We now present clinical outcome data and toxicity in a long-term follow-up with individual absorbed dose estimations.

Methods: Twelve patients with relapsed EOC, achieving a second complete or near complete response with chemotherapy received i.p. treatment with escalating (20 to 215 MBq/L) activity concentrations of 211At-MX35 F(ab')₂.

Results: The activity concentration was escalated to 215 MBq/L without any dose limiting toxicities. Most toxicities were low-grade and likely related to the treatment procedure, not clearly linked to the α -particle irradiation with no observed hematological toxicity. One grade 3 fatigue, and one grade 4 intestinal perforation during catheter implantation was observed. Four patients had a survival >6 years, one of whom did not relapse. At progression chemotherapy was given without signs of reduced tolerability. Overall median survival was 35 months with a 1-, 2-, 5-, and 10-year survival of 100%, 83%, 50% and 25%.

Calculations of the absorbed doses showed that a lower specific activity is associated with a lower single cell dose, whereas a high specific activity may result in a lower central dose in microtumors. Individual differences in absorbed dose to possible micro-tumors were due to variations in administered activity and the specific activity.

Conclusion: No apparent signs of radiation-induced toxicity, or decreased tolerance to relapse therapy were observed. The dosimetric calculations show that further optimization is advisable to increase the efficacy and reduce possible long-term toxicity.

Funding Agency

Swedish Research Council; the Swedish Cancer Society; the King Gustav V Clinic Research Foundation

Email Address

andreas.hallqvist@gu.se

Presentation Type

Contributed Oral

Primary authors: Dr PER, Albertsson (Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden); Dr HALLQVIST, Andreas (Dept. of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden)

Co-authors: Dr HÅKAN, Andersson (Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden); Dr KARIN, Bergmark (Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden); Mr TOM, Bäck (Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden); Dr PERNILLA, Dahm-Kähler (Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden); Dr JENSEN, Holger (PET and Cyclotron unit, Copenhagen University Hospital); Prof. RAGNAR, Hultborn (Department of Oncology, Institute of

Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden); Prof. LARS, Jacobsson (Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden); Dr MIA, Johansson (Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden); PALM, Stig (University of Gothenburg); Dr LINDEGREN, Sture (Department of Radiation Physics, Institute of Clinical Sciences Sahlgrenska Academy at Gotehnburg University)

Presenter: Dr PER, Albertsson (Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden)